Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection

Retrovirology

Volumn 4, Issue , 2007, Pages

  Van Rompay, Koen K A ^a   Johnson, Jeffrey A ^b   Blackwood, Emily J ^a   Singh, Raman P ^a   Lipscomb, Jonathan ^b   Matthews, Timothy B ^c   Marthas, Marta L ^a   Pedersen, Niels C ^c   Bischofberger, Norbert ^d   Heneine, Walid ^b   North, Thomas W ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; VIRUS RNA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERA; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SELECTIVITY; EVIDENCE BASED MEDICINE; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE DEPLETION; MACACA; MONOTHERAPY; MUTATIONAL ANALYSIS; NONHUMAN; PERSISTENT VIRUS INFECTION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; VIREMIA; VIRUS IMMUNITY; VIRUS MUTANT; AMINO ACID SUBSTITUTION; ANIMAL; ANTIBIOTIC RESISTANCE; BLOOD; DISEASE MODEL; GENETIC SELECTION; GENETICS; IMMUNOLOGY; MISSENSE MUTATION; MONKEY DISEASE; SIMIAN IMMUNODEFICIENCY VIRUS; VIROLOGY; VIRUS LOAD;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

ADENINE; AMINO ACID SUBSTITUTION; ANIMALS; ANTI-HIV AGENTS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; LYMPHOCYTE DEPLETION; MACACA; MUTATION, MISSENSE; PHOSPHONIC ACIDS; RNA, VIRAL; SELECTION (GENETICS); SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD; VIREMIA;

EID: 34247380296     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-4-25     Document Type: Article

References (96)

1. Margot NA Isaacson E McGowan I Cheng A Miller MD Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: Genotypic, phenotypic, and rebound analyses J Acquir Immune Defic Syndr 2003 33 15-21 12792350
2. Wainberg MA Miller MD Quan Y Salomon H Mulato AS Lamy PD Margot NA Anton KE Cherrington JM In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA Antivir Ther 1999 4 87-94 10682153
3. Gallant JE Staszewski S Pozniak AL DeJesus E Suleiman JM Miller MD Coakley DF Lu B Toole JJ Cheng AK Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial JAMA 2004 292 191-201 15249568 10.1001/ jama.292.2.191
4. Mauss S Milinkovic A Hoffman C Holm S Berger F Martínez E Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine AIDS 2005 19 101-103 15627042
5. McColl DJ Margot NA Wulfsohn M Coakley DF Cheng AK Miller MD Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate J Acquir Immune Defic Syndr 2004 37 1340-1350 15483463 10.1097/ 00126334-200411010-00002
6. Maitland D Moyle G Hand J Mandalia S Boffito M Nelson M Gazzard B Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/ efavirenz: 12-week results from a randomized trial AIDS 2005 19 1183-1188 15990571 10.1097/01.aids.0000176218.40861.14
7. Delaunay C Brun-Vezinet F Landman R Collin G Peytavin G Trylesinski A Flandre P Miller M Descamps D Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021) J Virol 2005 79 9572-9578 16014919 10.1128/ JVI.79.15.9572-9578.2005 1181609
8. Wirden M Marcelin AG Tubiana R Valantin MA Ghosn J Duvivier C Dominguez S Paris L Agher R Peytavin G Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level J Acquir Immune Defic Syndr 2004 36 876-878 15213573 10.1097/00126334-200407010-00016
9. Ruane PJ Luber AD K65R-Associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens MedGenMed 2004 6 31 1395806 15266257
10. Kuritzkes DR Less than the sum of its parts: Failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen J Infect Dis 2005 192 1867-1868 16267755 10.1086/498070
11. Gallant JE Rodriguez AE Weinberg WG Young B Berger DS Lim ML Liao Q Ross L Johnson J Shaefer MS Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects J Infect Dis 2005 192 1921-1930 16267763 10.1086/498069
12. Hirsch MS Brun-Vezinet F Clotet B Conway B Kuritzkes DR D'Aquila RT Demeter LM Hammer SM Johnson VA Loveday C Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel Clin Infect Dis 2003 37 113-128 12830416 10.1086/375597
13. White KL Margot NA Wrin T Petropoulos CJ Miller MD Naeger LK Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity Antimicrob Agents Chemother 2002 46 3437-3446 12384348 10.1128/AAC.46.11.3437-3446.2002 128721
14. Wirden M Malet I Derache A Marcelin AG Roquebert B Simon A Kirstetter M Joubert LM Katlama C Calvez V Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution AIDS 2005 19 630-632 15802984 10.1097/01.aids.0000163942.93563.fd
15. Deval J Navarro JM Selmi B Courcambeck J Boretto J Halfon P Garrido-Urbani S Sire J Canard B A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions J Biol Chem 2004 279 25489-25496 15044478 10.1074/jbc.M313534200
16. Moyle GJ The K65R mutation: Selection, frequency, and possible consequences AIDS Read 2004 14 595-597 601-593. 15570671
17. Parikh UM Barnas DC Faruki H Mellors JW Antagonism between the HIV-1 reverse-transciptase mutation K65R and thymidine-analogue mutations at the genomic level J Infect Dis 2006 194 651-660 16897664 10.1086/505711
18. Van Rompay KKA Greenier JL Marthas ML Otsyula MG Tarara RP Miller CJ Pedersen NC A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques Antimicrob Agents Chemother 1997 41 278-283 163702 9021180
19. Van Rompay KKA Cherrington JM Marthas ML Berardi CJ Mulato AS Spinner A Tarara RP Canfield DR Telm S Bischofberger N Pedersen NC 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques Antimicrob Agents Chemother 1996 40 2586-2591 163581 8913470
20. Van Rompay KKA Singh RP Pahar B Sodora DL Wingfield C Lawson JR Marthas ML Bischofberger N CD8+ cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment J Virol 2004 78 5324-5337 15113912 10.1128/JVI.78.10.5324-5337.2004 400346
21. Van Rompay KKA Cherrington JM Marthas ML Lamy PD Dailey PJ Canfield DR Tarara RP Bischofberger N Pedersen NC 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA Antimicrob Agents Chemother 1999 43 802-812 89210 10103184
22. Van Rompay KK Singh RP Brignolo LL Lawson JR Schmidt KA Pahar B Canfield DR Tarara RP Bischofberger N Marthas ML The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters J Acquir Immune Defic Syndr 2004 36 900-914 10.1097/ 00126334-200408010-00003 15220696
23. Witvrouw M Pannecouque C Switzer WM Folks TM De Clercq E Heneine W Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis Antivir Ther 2004 9 57-65 15040537
24. Uberla K Stahl-Hennig C Böttiger D Mätz-Rensing K Kaup FJ Li J Haseltine WA Fleckenstein B Hunsmann G Öberg B Sodroski J Animal model for the therapy of acquired immunodefiency syndrome with reverse transcriptase inhibitors Proc Natl Acad Sci USA 1995 92 8210-8214 7545297 10.1073/pnas.92.18.8210 41126
25. North TW Van Rompay KKA Higgins J Matthews TB Wadford DA Pedersen NC Schinazi RF Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1 J Virol 2005 79 7349-7354 15919889 10.1128/ JVI.79.12.7349-7354.2005 1143671
26. Rosenwirth B ten Haaft P Bogers WMJM Nieuwenhuis IG Niphuis H Kuhn E-M Bischofberger N Heeney JL Überla K Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques J Virol 2000 74 1704-1711 10644340 10.1128/ JVI.74.4.1704-1711.2000 111645
27. Ten Haaft P Verstrepen B Überla K Rosenwirth B Heeney J A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques J Virol 1998 72 10281-10285 110614 9811776
28. Mori K Yasumoti Y Sawada S Villinger F Sugama K Rosenwirth B Heeney JL Überla K Yamazaki S Ansari AA Rübsammen-Waigmann H Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection J Virol 2000 74 5747-5753 10846052 10.1128/ JVI.74.13.5747-5753.2000 112067
29. Rosenwirth B Bogers WM Nieuwenhuis IG Haaft PT Niphuis H Kuhn EM Bischofberger N Erfle V Sutter G Berglund P An anti-HIV strategy combining chemotherapy and therapeutic vaccination J Med Primatol 1999 28 195-205 10593486
30. Deeks SG Barditch-Crovo P Lietman PS Hwang F Cundy KC Rooney JF Hellmann NS Safrin S Kahn J Safety, pharmacokinetics and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults Antimicrob Agents Chemother 1998 42 2380-2384 105837 9736567
31. Hofman MJ Higgins J Matthews TB Pedersen NC Tan C Schinazi RF North TW Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1 Antimicrob Agents Chemother 2004 48 3483-3490 15328115 10.1128/AAC.48.9.3483-3490.2004 514752
32. Balzarini J De Clercq E Überla K SIV/HIV-1 hybrid virus expressing the reverse transcriptase gene of HIV-1 remains sensitive to HIV-1-specific reverse transcriptase inhibitors after passage in rhesus macaques J Acquir Immune Defic Syndr Hum Retrovirol 1997 15 1-4 9215647
33. Wadford DA Higgins J Van Rompay KKA Pedersen NC North TW Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV 2007
34. Margot NA Waters JM Miller MD In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and Lamivudine Antimicrob Agents Chemother 2006 50 4087-4095 16982781 10.1128/AAC.00816-06 1693985
35. White KL Chen JM Margot NA Wrin T Petropoulos CJ Naeger LK Swaminathan S Miller MD Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations Antimicrob Agents Chemother 2004 48 992-1003 14982794 10.1128/AAC.48.3.992-1003.2004 353090
36. Van Rompay KKA Brignolo LL Meyer DJ Jerome C Tarara R Spinner A Hamilton M Hirst LL Bennett DR Canfield DR Biological effects of short-term and prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA; tenofovir) to newborn and infant rhesus macaques Antimicrob Agents Chemother 2004 48 1469-1487 15105094 10.1128/AAC.48.5.1469-1487.2004 400569
37. Will a pill a day prevent HIV? Anticipating the results of the tenofovir "PREP" trials http://avac.org/pdf/tenofovir.pdf
38. Horton H Vogel TU Carter DK Vielhuber K Fuller DH Shipley T Fuller JT Kunstman KJ Sutter G Montefiori DC Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239 J Virol 2002 76 7187-7202 12072518 10.1128/JVI.76.14.7187-7202.2002 136301
39. Lifson JD Piatak M Jr Cline AN Rossio JL Purcell J Pandrea I Bischofberger N Blanchard J Veazey RS Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge J Med Primatol 2003 32 201-210 14498980 10.1034/j.1600-0684.2003.00026.x
40. Mothé BR Weinfurter J Wang C Rehrauer W Wilson N Allen TM Allison DB Watkins DI Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication J Virol 2003 77 2736-2740 12552014 10.1128/JVI.77.4.2736-2740.2003 141082
41. Mothe BR Horton H Carter DK Allen TM Liebl ME Skinner P Vogel TU Fuenger S Vielhuber K Rehrauer W Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection J Virol 2002 76 875-884 11752176 10.1128/jvi.76.2.875-884.2002 136839
42. Hazuda DJ Young SD Guare JP Anthony NJ Gomez RP Wai JS Vacca JP Handt L Motzel SL Klein HJ Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques Science 2004 305 528-532 15247437 10.1126/science.1098632
43. 5Van Rompay KKA Antiretroviral drug studies in non-human primates: A valid animal model for innovative drug efficacy and pathogenesis studies AIDS Reviews 2005 7 67-83 16092501
44. Resino S Bellón JM Sánchez-Ramón S Gurbindo D León JA Munoz-Fernández A CD8+ T-cell numbers predict the response to antiviral therapy in HIV-1 infected children Pediatr Res 2003 53 309 -312 12538791 10.1203/01.PDR.0000047652.58958.96
45. Wood E Hogg RS Yip B Harrigan PR Montaner JS Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy? J Acquir Immune Defic Syndr 2005 38 289-295 15735446
46. Buseyne F Scott-Algara D Bellal N Burgard M Rouzioux C Blanche S Riviere Y The frequency of HIV-specific interferon-gamma-producing CD8 T cells Is associated with both age and level of antigenic stimulation in HIV-1-infected children J Infect Dis 2005 192 1781-1786 16235177 10.1086/ 497152
47. Phillips AN Staszewski S Weber R Kirk O Francioli P Miller V Vernazza P Lundgren JD Ledergerber B HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load JAMA 2001 286 2560-2567 11722270 10.1001/jama.286.20.2560
48. Malhotra U Holte S Dutta S Berrey MM Delpit E Koelle DM Sette A Corey L McElrath MJ Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment J Clin Invest 2001 107 505-517 199253 11181650
49. Blankson JN Siliciano RF MHC class II genotype and the control of viremia in HIV-1-infected individuals on highly active antiretroviral therapy J Clin Invest 2001 107 549-551 199437 11238554
50. Schooley RT Ruane P Myers RA Beall G Lampiris H Berger D Chen S-S Miller MD Isaacson E Cheng AK for the Study 902 Team Tenofovir DF in antiretroviral-experienced patients: Results from a 48-week, randomized, double-blind study AIDS 2002 16 1257-1263 12045491 10.1097/ 00002030-200206140-00008
51. Barditch-Crovo P Deeks SG Collier A Safrin S Coakley DF Miller M Kearney BP Coleman RL Lamy PD Kahn JO Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults Antimicrob Agents Chemother 2001 45 2733-2739 11557462 10.1128/AAC.45.10.2733-2739.2001 90724
52. Louie M Hogan C Hurley A Simon V Chung C Padte N Lamy P Flaherty J Coakley D Di Mascio M Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals AIDS 2003 17 1151-1156 12819516 10.1097/ 00002030-200305230-00006
53. Lloyd RMJ Huong J Rouse E Gerondelis P Lim M Shaefer M Rodriguez A Gallant J Lanier R Ross LL HIV-1 RT mutations K70E and K65R are not present on the same viral genome when both mutations are detected in plasma 45th Annual ICAAC-Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, D.C 2005
54. Ross L Gerondelis P Liao Q Wine B Lim M Shaefer M Rodriguez A Gallant J Limoli K Huang W Selection of the HIV-1 reverse transcriptase mutation K70E in antiretroviral-naïve subjects treated with tenofovir/ abacavir/lamivudine therapy Antiviral Therapy 2005 10 S102
55. Mulato AS Lamy PD Miller MD Li W-X Anton KE Hellmann NS Cherrington JM Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy Antimicrob Agents Chemother 1998 42 1620-1628 105656 9660994
56. Cherrington JM Mulato AS Fuller MD Chen MS Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro Antimicrob Agents Chemother 1996 40 2212-2216 163503 8878611
57. Delaugerre C Roudiere L Peytavin G Rouzioux C Viard JP Chaix ML Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF J Clin Virol 2005 32 241-244 15722030 10.1016/j.jcv.2004.05.020
58. Kagan R Ross L Winters M Merigan T Heseltine P Lewinski M Adefovir-associated HIV-1 RT mutation K70E in the age of tenofovir Antiviral Therapy 2005 10 S103
59. HIV Drug Resistance Database http://hivdb.stanford.edu/
60. Miller MD Lamy PD Fuller MD Mulato AS Margot NA Cihlar T Cherrington JM Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity Mol Pharmacol 1998 54 291-297 9687570
61. Frost SDW Nijhuis M Schuurman R Boucher CAB Leigh Brown AJ Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: The relative roles of drift and selection J Virol 2000 74 6262-6268 10864635 10.1128/JVI.74.14.6262-6268.2000 112131
62. Tsai C-C Follis KE Beck TW Sabo A Grant RF Bischofberger N Benveniste RE Prevention of simian immunodeficiency virus infection in macaques by 9-(2-phosphonylmethoxypropyl)adenine (PMPA) Science 1995 270 1197-1199 7502044 10.1126/science.270.5239.1197
63. Lifson JD Rossio JL Arnaout R Li L Parks TL Schneider DK Kiser RF Coalter VJ Walsh G Imming RJ Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment J Virol 2000 74 2584-2593 10684272 10.1128/JVI.74.6.2584-2593.2000 111746
64. Silvera P Racz P Racz K Bischofberger N Crabbs C Yalley-Ogunro J Greenhouse J Bo Jiang J Lewis MG Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques AIDS Res Hum Retroviruses 2000 16 791-800 10826485 10.1089/088922200308783
65. Miller MD Margot N Lu B Zhong L Chen SS Cheng A Wulfsohn M Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients J Infect Dis 2004 189 837 846 14976601 10.1086/381784
66. Rhee SY Fessel WJ Zolopa AR Hurley L Liu T Taylor J Nguyen DP Slome S Klein D Horberg M HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance J Infect Dis 2005 192 456-465 15995959 10.1086/431601
67. Khanlou H Yeh V Guyer B Farthing C Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients AIDS Patient Care STDS 2005 19 135-140 15798380 10.1089/apc.2005.19.135
68. Castagna A Danise A Menzo S Galli L Gianotti N Carini E Boeri E Galli A Cernuschi M Hasson H Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study) AIDS 2006 20 795-803 16549962 10.1097/ 01.aids.0000218542.08845.b2
69. Danise A Tiberi S Galli L Lamivudine monotherapy in failing HIV-1 infected subjects, harbouring the M184V mutation: 72-week follow-up Programs and abstracts of the 10th European AIDS Conference, November 17-20; Dublin, Ireland 2005
70. Deeks SG Hoh R Neilands TB Liegler T Aweeka F Petropoulos CJ Grant RM Martin JN Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection J Infect Dis 2005 192 1537-1544 16206068 10.1086/496892
71. Kuritzkes DR Quinn JB Benoit SL Shugarts DL Griffin A Bakhtiari M Poticha D Eron JJ Fallon MA Rubin M Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients AIDS 1996 10 975-981 8853730
72. Eron JJ Benoit SL Jemsek J MacArthur RD Santana J Quinn JB Kuritzkes DR Fallon MA Rubin M for the North American HIV Working Group Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter N Engl J Med 1995 333 1662-1669 7477218 10.1056/NEJM199512213332502
73. Schuurman R Nijhuis M R. VL Schipper P De Jong D Collis P Danner SA Mulder J Loveday C Christoperson C Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC) J Infect Dis 1995 171 1411-1419 7539472
74. Richman DD Havlir D Corbeil J Looney D Ignacio C Spector SA Sullivan J Cheeseman S Barringer K Pauletti D Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy J Virol 1994 68 1660-1666 236624 7509000
75. Emu B Sinclair E Favre D Moretto WJ Hsue P Hoh R Martin JN Nixon DF McCune JM Deeks SG Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment J Virol 2005 79 14169-14178 16254352 10.1128/JVI.79.22.14169-14178.2005 1280210
76. Deeks SG Martin JN Sinclair E Harris J Neilands TB Maecker HT Hagos E Wrin T Petropoulos CJ Bredt B McCune JM Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1 J Infect Dis 2004 189 312-321 14722897 10.1086/380098
77. Alatrakchi N Duvivier C Costagliola D Samri A Marcelin A Kamkamidze G Astriti M Agher R Calvez V Autran B Katlama C Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication AIDS 2005 19 25-33 15627030 10.1097/ 00002030-200501030-00003
78. Price DA Scullard G Oxenius A Braganza R Beddows SA Kazmi S Clarke JR Johnson GE Weber JN Phillips AN Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity J Virol 2003 77 6041-6049 12719595 10.1128/JVI.77.10.6041-6049.2003 154002
79. Forthal DN Landucci G Cole KS Marthas M Becerra JC Van Rompay K Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells J Virol 2006 80 9217-9225 16940533 10.1128/JVI.02746-05 1563916
80. Metzner KJ Binley JM Gettie A Marx P Nixon DF Connor RI Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques Retrovirology 2006 3 97 17184540 10.1186/1742-4690-3-97 1769512
81. Van Rompay KKA Marthas ML Bischofberger N Tenofovir primes rhesus macaque cells in vitro for enhanced interleukin-12 secretion Antiviral Res 2004 63 133-138 15302142 10.1016/j.antiviral.2004.04.002
82. Nevins AB Wirden M Rhee SY Taylor J Fessel WJ Horberg M Scarsella A Lee SY Towner W Calvez V Virological response to antiretroviral therapy in the setting of the K65R mutation Antiviral Therapy 2006 11 S92
83. Chappell B Margot NA Miller MD Long-term virologic follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R mutation in HIV-1 RT 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC (Dec. 16-19) 2005
84. National Research Council Guide for the care and use of laboratory animals Washington, D. C.: National Academy Press 1996
85. Soderberg K Denekamp L Nikiforow S Sautter K Desrosiers RC Alexander L A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase J Virol 2002 76 5803-5806 11992009 10.1128/ JVI.76.11.5803-5806.2002 137045
86. Schmitz JE Kuroda MJ Santra S Sasseville VG Simon MA Lifton MA Racz P Tenner-Racz K Dalesandro M Scallon BJ Control of viremia in simian immunodeficiency virus infection by CD8+ T lymphocytes Science 1999 283 857-860 9933172 10.1126/science.283.5403.857
87. Schmitz JE Simon MA Kuroda MJ Lifton MA Ollert MW Vogel CW Racz P Tenner-Racz K Scallon BJ Dalesandro M A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody Am J Pathol 1999 154 1923-1932 10362819
88. Cline AN Bess JW Piatak M Jr Lifson JD Highly sensitive SIV plasma viral load assay: Practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS J Med Primatol 2005 34 303-312 16128925 10.1111/ j.1600-0684.2005.00128.x
89. Lifson JD Rossion JL Piatak MJ Parks T Li L Kiser R Coalter V Fisher B Flynn BM Czajak S Role of CD8+ lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment J Virol 2001 75 10187-10199 11581387 10.1128/JVI.75.21.10187-10199.2001 114593
90. Van Rompay KKA Marthas ML Ramos RA Mandell CP McGowan EK Joye SM Pedersen NC Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: Oral 3′-azido-3′-deoxythymidine prevents SIV infection Antimicrob Agents Chemother 1992 36 2381-2386 284339 1489181
91. Van Rompay KKA Otsyula MG Marthas ML Miller CJ McChesney MB Pedersen NC Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS Antimicrob Agents Chemother 1995 39 125-131 162497 7695293
92. Johnson JA Van Rompay KKA Delwart E Heneine W A sensitive real-time PCR assay for the K65R drug resistance mutation in SIV reverse transcriptase AIDS Res Hum Retroviruses 2006 22 912-916 16989618 10.1089/ aid.2006.22.912
93. Van Rompay KKA Dailey PJ Tarara RP Canfield DR Aguirre NL Cherrington JM Lamy PD Bischofberger N Pedersen NC Marthas ML Early short-term 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) treatment favorably alters subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques J Virol 1999 73 2947-2955 104054 10074144
94. Van Rompay KKA Matthews TB Higgins J Canfield DR Tarara RP Wainberg MA Schinazi RF Pedersen NC North TW Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase J Virol 2002 76 6083-6092 12021341 10.1128/JVI.76.12.6083-6092.2002 136201
95. Knapp LA Lehmann E Piekarczyk MS Urvater JA Watkins DI A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing Tissue Antigens 1997 50 657 661 9458122
96. Evans DT Knapp LA Jing P Mitchen JL Dykhuizen M Montefiori DC Pauza CD Watkins DI Rapid and slow progressors differ by a single MHC class I haplotype in a family of MHC-defined rhesus macques infected with SIV Immunol Lett 1999 66 53-59 10203034 10.1016/S0165-2478(98)00151-5